NapaJen Pharma

NapaJen Pharma is a private, preclinical-stage biotech founded in 2015, headquartered in Seattle, USA, with a subsidiary in Japan. The company has developed a first-in-class drug delivery system (DDS) that selectively targets nucleic acid drugs to immune cells expressing the Dectin-1 receptor, such as macrophages and dendritic cells. Its platform enables both immunosuppressive and immunostimulatory therapies, with a lead candidate, NJA-730, having completed a Phase 1 trial. NapaJen operates a hybrid business model, pursuing both internal drug development and external partnerships to leverage its delivery platform.

Proprietary Drug Delivery System (DDS) that targets nucleic acid therapeutics to immune cells (e.g., macrophages, dendritic cells) via the Dectin-1 receptor. Enables selective delivery for immunosuppressive or immunostimulatory applications.

NapaJen competes in the targeted RNA delivery space against established players like Alnylam (GalNAc-conjugates for liver) and Arrowhead Pharmaceuticals, as well as numerous biotechs developing lipid nanoparticles, antibody conjugates, and other ligand-targeted systems for extra-hepatic delivery, particularly in immunology.